Literature DB >> 19693097

When mutants gain new powers: news from the mutant p53 field.

Ran Brosh1, Varda Rotter.   

Abstract

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies have modified our view of mutant p53 proteins, portraying them not as inert mutants, but rather as regulated proteins that influence the cancer cell transcriptome and phenotype. This influence is clinically manifested as association of TP53 mutations with poor prognosis and drug resistance in a growing array of malignancies. Here, we review recent studies on mutant p53 regulation, gain-of-function mechanisms, transcriptional effects and prognostic association, with a focus on the clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693097     DOI: 10.1038/nrc2693

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  187 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Authors:  A N Jain; K Chin; A L Børresen-Dale; B K Erikstein; P Eynstein Lonning; R Kaaresen; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.

Authors:  Oded Suad; Haim Rozenberg; Ran Brosh; Yael Diskin-Posner; Naama Kessler; Linda J W Shimon; Felix Frolow; Atar Liran; Varda Rotter; Zippora Shakked
Journal:  J Mol Biol       Date:  2008-10-30       Impact factor: 5.469

Review 4.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 5.  Cancer chemoresistance: the relationship between p53 and multidrug transporters.

Authors:  Jason A Bush; Gang Li
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

6.  Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.

Authors:  Pedro Kringen; Anna Bergamaschi; Eldri Undlien Due; Yun Wang; Elda Tagliabue; Jahn M Nesland; Aune Nehman; Neeme Tönisson; Anne-Lise Børresen-Dale
Journal:  Biotechniques       Date:  2005-11       Impact factor: 1.993

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

9.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  490 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

3.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

4.  A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes.

Authors:  Adam Shlien; Berivan Baskin; Maria Isabel W Achatz; Dimitrios J Stavropoulos; Kim E Nichols; Louanne Hudgins; Chantal F Morel; Margaret P Adam; Nataliya Zhukova; Lianne Rotin; Ana Novokmet; Harriet Druker; Mary Shago; Peter N Ray; Pierre Hainaut; David Malkin
Journal:  Am J Hum Genet       Date:  2010-11-12       Impact factor: 11.025

5.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

6.  Building p53.

Authors:  Tamara Terzian; Guillermina Lozano
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

7.  Antibody Responses to Streptococcus Gallolyticus Subspecies Gallolyticus Proteins in a Large Prospective Colorectal Cancer Cohort Consortium.

Authors:  Julia Butt; William J Blot; Lauren R Teras; Kala Visvanathan; Loïc Le Marchand; Christopher A Haiman; Yu Chen; Ying Bao; Howard D Sesso; Sylvia Wassertheil-Smoller; Gloria Y Ho; Lesley F Tinker; Richard M Peek; John D Potter; Timothy L Cover; Laura H Hendrix; Li-Ching Huang; Tim Waterboer; Michael Pawlita; Meira Epplein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

Review 8.  Regulation of cancer metabolism by O-GlcNAcylation.

Authors:  Zhonghua Li; Wen Yi
Journal:  Glycoconj J       Date:  2013-12-10       Impact factor: 2.916

9.  Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Authors:  Noa Rivlin; Shir Katz; Maayan Doody; Michal Sheffer; Stav Horesh; Alina Molchadsky; Gabriela Koifman; Yoav Shetzer; Naomi Goldfinger; Varda Rotter; Tamar Geiger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

10.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.